BOSTON—Biofourmis, a Singapore-based startup co-founded by Kuldeep Singh Rajput, has raised a $35 million Series B round of funding and will relocate its headquarters to Boston.
The Series B financing was co-led by Sequoia India and MassMutual Ventures. Other investors in the Series B financing include EDBI, the corporate investment arm of Singapore’s Economic Development Board; Chinese online healthcare platform Jianke, Openspace Ventures; Aviva Ventures and SGInnovate.
The round takes Biofourmis to $41.6 million raised to date, according to Crunchbase.
TechCrunch reported that Biofourmis CEO Kuldeep Singh Rajput moved to Singapore to start a PhD, but he dropped out to start the business with co-founder Wendou Niu in 2015 because he saw the potential to “predict disease before it happens,” he told TechCrunch in an interview.
Biofourmis uses a mobile app as a touch point to give patients tailored care and drug prescriptions after they are discharged from the hospital, according to TechCrunch news portal.
TechCrunch reported that Biofourmis is relocating its headquarters to Boston, but will retain its presence in Singapore, where it has 45 people who handle software and product development.
“The U.S. has been a major market focus since day one,” Singh Rajput told TechCrunch. “Being closer to customers and attracting the clinical data science pool is critical.”
